Press release
Breakthrough Treatments for Non-Hodgkin Lymphoma
The Business Research Company recently released a comprehensive report on the Global Non Hodgkin Lymphoma (NHL) Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.According to The Business Research Company's, The non hodgkin lymphoma (nhl) market size has grown strongly in recent years. It will grow from $9.34 billion in 2023 to $10.23 billion in 2024 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to increased incidence of nhl, advancements in diagnostics, chemotherapy and immunotherapy, clinical research and drug development, improved survival rates.
The non hodgkin lymphoma (nhl) market size is expected to see strong growth in the next few years. It will grow to $14.13 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to growing aging population, advancements in targeted therapies, immunotherapy innovations, precision medicine approaches, increasing awareness and early detection. Major trends in the forecast period include rise of biosimilars, integration of next-generation sequencing, adoption of car-t cell therapies, novel chemotherapy agents, real-world evidence and outcomes research.
Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report
Market Drivers and Trends:
The high prevalence of non-Hodgkin lymphoma is expected to propel the growth of the non-Hodgkin lymphoma market going forward. It is a cancer that develops in the lymphatic system, which is part of your immune system. The prevalence of non-Hodgkin lymphoma refers to the number of individuals in a population who are currently diagnosed with or living with the condition at a specific time. Non-Hodgkin lymphoma treatment helps improve outcomes for individuals already diagnosed with the condition by targeting and managing the cancer cells. For instance, in January 2023, according to the American Cancer Society, a US-based cancer health organization, non-Hodgkin lymphoma accounts for 4% of all cancers, and in 2023, it will affect around 80,550 Americans, including 44,880 males and 35,670 females. It also estimates that 20,180 people will die in 2023 because of non-Hodgkin lymphoma. Furthermore, in May 2022, according to the Canadian Cancer Society, a Canada-based national cancer charity, non-Hodgkin lymphoma would be diagnosed in 11,400 Canadians in the year 2022. It would claim the lives of 3,000 Canadians. Therefore, the high prevalence of non-Hodgkin lymphoma is driving the non-Hodgkin lymphoma market.
Advancements in drug innovations are a key trend gaining popularity in the non-Hodgkin lymphoma market. Companies operating in the non-Hodgkin market are focused on innovating new products to sustain their position in the market. For instance, in December 2022, Genentech Inc., a US-based biotechnology company, received FDA approval for Lunsumio, a novel bispecific antibody for treating relapsed or refractory follicular lymphoma. This antibody is a new class of fixed-duration cancer treatment immunotherapy, and it is a readily available and off-the-shelf treatment option patients do not need to wait to receive this immunotherapy treatment. The FDA approval is based on positive results from the Lunsumio Phase II GO29781 research in persons with extensively pretreated FL, particularly those at high risk of illness progression or unresponsive to prior treatments.
Key Benefits for Stakeholders:
• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=10676&type=smp
Major Key Players of the Market:
Bayer AG; Teva Pharmaceutical Industries Ltd.; F. Hoffmann La Roche Ltd.; Merck & Co. Inc.; Eli Lilly and Co.; Novartis AG; GlaxoSmithKline plc; AbbVie Inc.; AstraZeneca plc; Takeda Pharmaceutical Company Limited; Bristol Myers Squibb Co.; Pfizer Inc.; Celgene Corporation; Sanofi S.A.; Janssen Pharmaceuticals Inc.; Johnson & Johnson; Biogen Idec; Boehringer Ingelheim GmbH; Eisai Co. Ltd.; Gilead Sciences; Incyte Corporation; Karyopharm Therapeutics; Kite Pharma Inc.; Kyowa Hakko Kirin Co. Ltd.; MorphoSys AG; Nordic Nanovector ASA; Ono Pharmaceutical Co. Ltd.; Seattle Genetics Inc.; Spectrum Pharmaceuticals Inc.
Non Hodgkin Lymphoma (NHL) Market 2024 Key Insights:
• The non hodgkin lymphoma (nhl) market will grow to $14.13 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%.
• High Prevalence Of Non-Hodgkin Lymphoma Fuels Market Growth
• Bispecific Antibody Revolutionizes Treatment Options For Relapsed Lymphoma
• North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2023
We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=10676&type=smp
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Breakthrough Treatments for Non-Hodgkin Lymphoma here
News-ID: 3750128 • Views: …
More Releases from The Business Research Company

Global High-Resolution Anoscopy Market Outlook 2025-2034: Trends, Innovations, A …
The High-Resolution Anoscopy Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the High-Resolution Anoscopy Market Size and Projected Growth Rate?
The market size for high-resolution anoscopy has experienced significant growth over the past few years. The market is predicted to increase from $15.03 billion…

Condyloma Acuminata Treatment Market Size Projected To Reach $2.2 Billion By 203 …
"The Condyloma Acuminata Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Condyloma Acuminata Treatment Market Size During the Forecast Period?
In the past few years, the condyloma acuminata treatment market has seen significant growth. The market value, which is anticipated to…

Household Type Fans Market Forecast 2025-2034: Comprehensive Analysis And Growth …
"The Household Type Fans Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Household Type Fans Market?
The market size for household fans has seen consistent expansion in recent years. The projections indicate an increase from $32.22 billion in 2024…

Grain Fumigants Industry Report 2025-2034: Market Dynamics, Trends, And Forecast …
The Grain Fumigants Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Grain Fumigants Market Size During the Forecast Period?
The Grain Fumigants Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This…
More Releases for Hodgkin
Hodgkin Lymphoma Treatment Market Poised to Reach USD 15.70 Bn by 2030 at 8.3% C …
Opening Paragraph
According to a new report by Maximize Market Research, the global Hodgkin Lymphoma Treatment Market was valued at USD 8.98 billion in 2023 and is projected to reach nearly USD 15.70 billion by 2030, growing at a CAGR of 8.3%.
Curious to peek inside? Grab your sample copy of this report now:https://www.maximizemarketresearch.com/request-sample/124690/
Key Highlights
Market Size & CAGR: Valued at USD 8.98 Bn in 2023, forecast to grow to USD 15.70…
High Prevalence Of Non-Hodgkin Lymphoma Fuels Market Growth: The Driving Engine …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Non Hodgkin Lymphoma (NHL) Market Size Growth Forecast: What to Expect by 2025?
The market size for non hodgkin lymphoma (NHL) has consistently seen robust growth in recent times. It is anticipated to expand from $10.11 billion in 2024 to $11.01 billion in 2025, with a compound annual growth…
Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight
The market for Non Hodgkin Lymphoma has significant unmet medical necessities in terms of demand for innovative drugs and novel technologies. This is one of the major factors behind the market witnessing rapid growth in Non Hodgkin Lymphoma segment. Past few decades have witnessed an increased level of activity with regards to development of new identification systems and drug mechanisms. In recent years, there have been an increasing number of…
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017 | Market R …
Market Research Hub (MRH) has recently published a latest market study to its online portal, which is titled as “Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017” This study offers professional analysis of the current state of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Market.
Request Free Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1049067
Market Research HUB’s latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Pipeline Review, H1 2017, provides…
Non-Hodgkin Lymphoma - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Non-Hodgkin Lymphoma - Heat Map and Analysis to its growing collection of premium market research reports.
Non-Hodgkin lymphomas (NHL) are a heterogeneous group of malignancies that originate from lymphoid tissue, with varied clinical and biological features. There were an estimated 385,741 new cases of NHL and 199,630 deaths from NHL worldwide in 2012. NHLs are classified as either indolent (slow-growing)…
Blood Cancer (leukemia, Non-Hodgkin lymphoma, Hodgkin lymphoma, Multiple Myeloma …
Blood cancer is a general term used for the cancers that affect blood, bone marrow or lymphatic system. Most of these cancers start in bone marrow where blood cells (RBC, WBC and platelets) are produced from bone marrow stem cells. In cancerous condition, differentiation of bone marrow stem cells is interrupted to produce abnormal blood cells which hamper the normal functioning of the blood. There are 4 types of blood…